Marker Therapeutics (NASDAQ:MRKR) signed an agreement with CellReady, a newly formed Contract Development and Manufacturing Organization (CDMO) founded by John Wilson, Marker's co-founder and board ...
Marker Therapeutics, Inc. (NASDAQ:MRKR) on Tuesday provided an update on the progress and clinical observations from the Phase 1 APOLLO study investigating MT-601, a Multi-Antigen Recognizing (MAR)-T ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback